Facebook
Twitter
LinkedIn
ForwardPost-ECTRIMS 2015 Review and Analysis: Scientific and Therapeutic Advances in the Treatment of Multiple Sclerosis
This CME activity will give clinicians a well-rounded review and analysis from the 2015 ECTRIMS Meeting held in Barcelona, Spain. The faculty will communicate important information for clinical decision-making, as it relates to the comprehensive healthcare team, in the initiation of treatment and effectively communicating therapeutic options with the patient. The role of targeted therapeutics as well as the neurodegenerative and inflammatory processes of multiple sclerosis will be reviewed. The role of B cells in targeted MS therapy and new advances in that area will be identified. Expert faculty will generate practical ways for clinicians to address treatment barriers for patients with MS, while simultaneously developing personalized treatment plans.
Target Audience
Neurologists, and healthcare professionals responsible for the diagnosis, treatment, or management of patients with multiple sclerosis.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review emerging clinical science presented at ECTRIMS 2015, including the neurodegenerative and inflammatory processes of multiple sclerosis, and the role of targeted therapeutics.
- Evaluate strategies presented at ECTRIMS 2015 to develop personalized treatment plans to effectively address treatment barriers for patients with multiple sclerosis.
Faculty
| Fred Lublin, MD |
 | Suhayl S. Dhib-Jalbut, MD |
 | Patricia Coyle, MD
|
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflict of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Faculty or Presenter | Relationship Identified With: |
Fred Lublin, MD | Consultant/Advisor: Acorda Therapeutics, Inc.; Actelion Pharmaceuticals US, Inc; Akros Pharma, Inc; Bayer HealthCare Pharmaceuticals; BBB technologies; Bigoen Idec; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Hoffmann-La Roche Ltd; MedImmune, LLC; Novartis Pharmaceutical Corporation; Osmotica Pharmaceutical Corp; Questcor/Mallinckrodt; Receptos, Inc.; sanofi-aventis, U.S. LLC; Teva Neuroscience, Inc.; XenoPort, Inc. Grant/Research Support: Biogen Idec; Celgene; Genzyme Corporation; National Institutes of Health; National Multiple Sclerosis Society; Novartis Pharmaceuticals Corporation; Sanofi; Teva Neuroscience, Inc; Transparency Life Sciences Stock Ownership: Cognition Pharmaceuticals, Inc. Co-Chief Editor: Multiple Sclerosis and Related Diseases |
Suhayl S. Dhib-Jalbut, MD | Consultant/Advisor: Bristol-Myers Squibb Company; Genentech; Genzyme Corporation; Mallinckrodt Pharmaceuticals; EMD Serono, Inc.; Teva Neuroscience, Inc. Grant/Research Support: Biogen Idec; Teva Neuroscience, Inc. |
Patricia Coyle, MD | Consultant/Advisor: AbbVie, Inc.; Accordant; Acorda Therapeutics, Inc.; Bayer HealthCare Pharmaceuticals; Biogen Idec; Genzyme Corporation; sanofi-aventis U.S. LLC; Novartis Pharmaceuticals Corporation; EMD Serono, Inc.; Teva Neuroscience, Inc. Grant/Research Support: Actelion Pharmaceuticals US; Novartis Pharmaceuticals Corporation; Opexa Therapeutics |
Non-Faculty: Bernard M. Abrams, MD, Sandy Breslow, Alison Kemp, Timothy Hayes, MD, PhD, Kristen Scollon, Emma Gilmartin and Jaimie Kelly hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Financial Support
This CME activity is supported by an educational grant from Genentech, Inc.
Provider Information
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
Course Open Date: November 9, 2015 | Course Expiration Date: November 8, 2016
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician